June 1, 2014 – A new research study conducted by scientists at Verastem, Inc. and published in the Science Translational Medicine journal addresses effectiveness of cancer treatment drugs that target certain mesothelioma cancer stem cells. Specifically, the new study investigated the role of certain proteins in treating mesothelioma patients who lack the tumor suppressor merlin. Approximately 50% of all mesothelioma patients suffer from merlin loss.
The Verastem study data indicates that certain protein inhibitor treatment (including focal adhesion kinase or FAK inhibitor treatment) may increase the effectiveness of certain cancer treatment drugs in individuals with mesothelioma cancer cells lacking merlin. Verastem scientists focused their study on the compound VS-6063 which has been designed to target mesothelioma cancer stem cells through the use of a FAK protein inhibitor. Read more about this groundbreaking research in our previous blog.
These latest findings lend support to the worldwide clinical trials of VS-6063 being conducted at clinical sites in over 12 countries including the United States, Canada, Japan, Australia and the United Kingdom.
The Philadelphia Mesothelioma Attorneys at the Shein Law Help Victims Obtain Compensation
Dealing with an asbestos-related disease such as mesothelioma, asbestosis or lung cancer can be devastating to families who face staggering financial and personal losses. The dedicated mesothelioma attorneys at Shein Law have four decades of experience working with victims and their families and can give you the support and peace of mind you need. Our offices are conveniently located in Philadelphia, Pennsylvania and Pennsauken, New Jersey. To schedule a free consultation at a location convenient to you and your family, call our Pennsylvania mesothelioma lawyers at 1-877-SHEINLAW (743-4652) or contact us online.